Brii Biosciences Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BRIBF research report →
About the company
Brii Biosciences Limited, established in 2017 and headquartered in Beijing, China, is dedicated to advancing therapeutic solutions for infectious diseases and disorders affecting the central nervous system. Their diverse pipeline includes BRII-778 and BRII-732, both progressing through Phase I clinical trials for HIV patients. For Hepatitis B (HBV), they are evaluating BRII-179 and BRII-835 in a combined Phase 2 study; BRII-179 also stands as a recombinant protein-based HBV immunotherapeutic in Phase 1b/2a, while BRII-835 has completed Phase 2 for chronic HBV patients.
- CEO
- Zhi Hong
- IPO
- 2022
- Employees
- 98
- HQ
- Beijing, CN
Price Chart
- Market Cap
- $107.82M
- P/E
- -3.29
- P/S
- 37.15
- P/B
- 0.30
- EV/EBITDA
- -0.40
- Div Yield
- 0.00%
- Gross Margin
- 84.78%
- Op Margin
- -1534.06%
- Net Margin
- -1124.36%
- ROE
- -8.92%
- ROIC
- -12.68%
- Revenue
- $18.12M · -63.70%
- Net Income
- $-216,878,992 · 57.32%
- EPS
- $-0.30 · 57.14%
- Op Income
- $-295,905,623
- FCF YoY
- 23.31%
- 52W High
- $0.26
- 52W Low
- $0.15
- 50D MA
- $0.16
- 200D MA
- $0.20
- Beta
- 1.23
- Avg Volume
- 161
Get TickerSpark's AI analysis on BRIBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BRIBF coverage
Recent articles, reports, and earnings notes.
No research on BRIBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BRIBF report →Similar companies
Peers in the same neighborhood.